Company Overview and News

1
CBMG / Cellular Biomedicine Group, Inc. null

2018-05-31 sec.gov
Blueprint Cellular Biomedicine Grou
CBMG

1
BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

2018-05-08 reuters
* CELLULAR BIOMEDICINE GROUP INC - QTRLY LOSS PER SHARE $0.51 Source text for Eikon: Further company coverage:
CBMG

1
PHI Group Declares Special Stock Dividend and Spins off American Pacific Resources, Inc. Subsidiary

2018-04-25 globenewswire
New York, NY, April 25, 2018 (GLOBE NEWSWIRE) -- PHI Group, Inc., (www.phiglobal.com) (OTCQB:PHIL), a company focused on mergers and acquisitions and investments in natural resources, energy, agriculture and special situations, announced today that American Pacific Resources, Inc. (www.aprgold.com), a wholly owned subsidiary of the Company, will be spun off into its own separate publicly traded entity.
CBMG PHIL

1
CBMG / Cellular Biomedicine Group, Inc. S-3/A

2018-04-02 sec.gov
Blueprint As filed with the Securit
CBMG

18
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center

2018-03-25 seekingalpha
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson in attendance. The new research center, which may be called the Watson Research Center of Life Science, will strive to find new, less expensive solutions to the problem of cancer and will be staffed by more than 1,000 scientists.
DOVA CICHY AVMXY CASI AVMXF NVS CBMG AVH CICHF CCB 0939

5
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders

2018-03-23 globenewswire
SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 27, 2018. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd.
TMO CBMG

5
CBMG异体脂肪间充质祖细胞制剂AlloJoin™治疗膝骨关节炎I期临床试验获得初步的安全和有效性结果

2018-03-21 globenewswire
关于西比曼生物科技集团(Cellular Biomedicine Group): Cellular Biomedicine Group, Inc.(NASDAQ:CBMG)是一家专门从事肿瘤免疫细胞治疗和退行性疾病干细胞治疗制剂研发的生物科技公司。目前正在中国开展肿瘤免疫细胞治疗制剂和膝骨关节炎干细胞治疗制剂的临床试验。临床试验用免疫细胞和干细胞制剂均出自符合GMP要求的中国实验室。CBMG目前拥有十二条独立的细胞生产线,这些生产线均按中国与美国 GMP 标准进行设计与管理。西比曼生物科技(上海)有限公司已经与美国GE Healthcare和Thermo Fisher Scientific分别联合建立了“联合细胞疗法联合实验室”和“联合细胞疗法技术创新应用中心”。这些联合实验室的建立,将进一步改进和优化CBMG细胞生产制备的标准化流程。CBMG已经在中国完成Rejoin™(自体脂肪来源的间充质祖细胞)治疗膝骨关节炎(KOA)的I/IIa期(NCT01809769 )和IIb期( NCT02162693)两项临床试验,以及AlloJoin™(异体脂肪来源的间充质祖细胞)治疗膝骨关节炎(KOA)的I期临床试验。目前正在中国开展的CAR-T细胞的I期临床试验,包括C-CAR011治疗弥漫性大B细胞淋巴瘤(Diffuse Large B-cell Lymphoma / DLBCL)和非霍奇金氏淋巴瘤(Non-Hodgkin Lymphoma / NHL)临床试验,以及C-CAR011治疗成人急性淋巴细胞白血病(Acute Lymphoblastic Leukemia / ALL)临床试验。在2018年第一季度,CMBG入选知名投资机构Loncar Investments设立的 “中国生物医药指数 (Loncar China BioPharma Index, LCHINA)”企业名单。如需了解 更多信息,请访问:www.
TMO CBMG

1
BRIEF-Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial

2018-03-16 reuters
* CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL
CBMG

5
Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial

2018-03-16 globenewswire
SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announces 48-week clinical data from the Phase I clinical trial in China for its allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy AlloJoin™ for Knee Osteoarthritis (KOA).
TMO CBMG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 15117P102